Business Context and Reporting Period
This Form 8-K, filed on February 7, 2019, reports the completion of the separation and subsequent merger of Henry Schein, Inc.'s animal health business. The transaction involved the distribution of the business to Covetrus, Inc., followed by Covetrus's merger with Direct Vet Marketing, Inc. (d/b/a Vets First Choice). Following this event, Henry Schein no longer consolidates the financial results of Covetrus.
Key Financial Metrics and Transaction Details
- Cash Proceeds: Henry Schein received a tax-free distribution of $1,120.0 million from Covetrus.
- Share Sale Proceeds: Covetrus issued shares to institutional investors for $361.1 million, with proceeds distributed to Henry Schein.
- Ownership Structure Post-Merger: Approximately 63% of Covetrus common stock was owned by Henry Schein stockholders and Share Sale Investors, while approximately 37% was owned by Vets First Choice stockholders.
- Financial Statements: The filing includes unaudited pro forma consolidated financial statements reflecting the separation as if it occurred on January 1, 2017, for periods ending September 29, 2018, and fiscal years 2015 through 2017.
Material Changes Versus Prior Period
The primary material change is the divestiture of the Henry Schein Animal Health Business. Consequently, Henry Schein will no longer consolidate Covetrus's financial results. The filing notes that certain general corporate overhead expenses not specifically related to Covetrus will remain in Henry Schein's continuing operations rather than being classified as discontinued operations.
Outlook, Risks, and Management Commentary
Management states that the unaudited pro forma financial statements are provided for illustrative and informational purposes only and are not necessarily indicative of future results. The pro forma adjustments are based on assumptions management believes are reasonable and factually supportable. The filing does not provide specific forward-looking guidance on revenue or earnings for the remaining business, nor does it detail specific risks beyond the standard disclaimers regarding pro forma data.
Key Facts for Investor Verification
- Verify the exact composition of the $1,120.0 million tax-free distribution and its impact on Henry Schein's liquidity.
- Review Exhibit 99.1 to understand the pro forma revenue and profit impact of removing the animal health segment.
- Confirm the treatment of general corporate overhead expenses in continuing operations versus discontinued operations.
- Assess the independence of Covetrus as a publicly traded entity on the Nasdaq Global Select Market.